Disc Medicine CEO John Quisel sells $2.6m in shares

John D. Quisel, CEO and Director of Disc Medicine Inc., sold 33,000 shares of the company's stock for a total of $2.6 million on August 17, 2026. This distribution of shares was carried out under a pre-approved trading plan that he established on March 12, 2026. The shares were traded in batches at prices ranging from $78.1061 to $79.842.

Quisel sold 8,400 shares within the $77.50-$78.49 range, 12,712 shares between $78.53 and $79.52, and the remaining 11,888 shares within the $79.53-$80.02 bracket. As of the sale date, the stock price stood at $80.20, indicating a substantial 38% increase over the previous year, though it is noted that the stock's price can be quite volatile.

On the same day Quisel sold shares, he also bought 33,000 shares by exercising stock options, resulting in a total expenditure of $445,500. These options were part of a larger award where shares are granted in 48 equal monthly payments following December 29, 2022, contingent on Quisel's continued employment. After these transactions, Quisel now directly owns 226,064 shares of Disc Medicine common stock, in addition to owning 91,586 derivative securities in the form of stock options.

An analysis by InvestingPro suggests that the stock is presently overvalued, placing it among the most overvalued stocks currently tracked. Recently, Disc Medicine Inc. shared updated results from clinical trials for two experimental treatments at the European Hematology Association Annual Meeting. The RALLY-MF trial, testing a medication known as DISC-0974, showed promising outcomes in patients with myelofibrosis and anemia.

Furthermore, Disc Medicine has reached an agreement with the FDA on the approval pathway for bitopertin, an investigational treatment for erythropoietic protoporphyria. The FDA has indicated that the ongoing Phase 3 APOLLO study could potentially lead to a traditional approval if the trials are successful. Disc Medicine also announced the initiation of an expanded access program for bitopertin in the U.S., aimed at patients with erythropoietic protoporphyria and X-linked protoporphyria who do not have sufficient alternative treatments available.

This program is open to eligible patients aged 12 and above. Analyst firms have offered their opinions on Disc Medicine's recent developments; Cantor Fitzgerald has maintained an Overweight rating with a $125 price target, highlighting upcoming pipeline catalysts. Stifel has also reiterated a Buy rating with an $111 price target following the presentation of the RALLY-MF trial data.

These recent events illustrate significant advancements in Disc Medicine's clinical and regulatory endeavors.